ArticleBMC pulmonary medicine2025
Nomogram and risk-score for predicting overall survival and risk stratification in patients with sarcomatoid non-small cell lung cancer: a multicenter study of 135 patients.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundTo explore the clinical data and CT findings associated with outcomes prognosis of patients with sarcomatoid non-small cell lung cancer (s-NSCLC). MATERIALS AND
methodsIn this retrospective study, s-NSCLC patients who underwent contrast-enhanced thoracic CT from January 2013 to June 2023 at three centers were enrolled. Clinicoradiological data, including sex, age, smoking status, tumor-node-metastasis (TNM) classification, tumor size, tumor location, calcification, vacuole/cavity, hydrothorax, low-attenuation area (LAA) ratio and peritumoral ground-glass opacity (GGO) or nodules were calculated. Clinical and CT findings associated with overall survival (OS) were evaluated by a multivariate Cox regression model.
resultsA total of 135 patients with s-NSCLC in three centers were included. s-NSCLC patients were more likely to be elderly male smokers. The mean age and tumor size at diagnosis were 62 years and 5.8 cm, respectively. The median survival time of patients with s-NSCLC was 9 (95% CI: 7, 11) months. The 1-, 2- and 3-year OS rates of the s-NSCLC patients were 36.6%, 26.7% and 21.4%, respectively. s-NSCLC is often peripherally located (98/135, 70.4%). Calcification and vacuole/cavity were rare in s-NSCLC lesions. The hydrothorax was present in 36/135 (26.7%) s-NSCLC patients. The s-NSCLC lesions usually presented with LAA (87/135, 80.6%), and the median LAA ratio was 30.8% (interquartile range, IQR: 10.6%, 50.7%). In the multivariate Cox regression analysis, smoking status (hazard ratio, HR = 1.668 [95% CI: 1.040, 2.678]), tumor size (HR = 1.818 [95% CI: 1.167, 2.832]), peritumoral GGO or nodules (HR = 2.064 [95% CI: 1.090, 3.909]) and M stage (HR = 2.479 [95% CI: 1.476, 4.164]) were associated with increased mortality, whereas surgery (HR = 0.467 [95% CI: 0.274, 0.797]) was associated with decreased mortality. We constructed a nomogram for predicting the 1-, 2- and 3-year OS rates of s-NSCLC patients, and the AUCs were 0.867, 0.905 and 0.911, respectively. Risk-score = 0.512×smoking status + 0.598×tumor size + 0.725×peritumoral GGO or nodules+(-0.761)×surgery + 0.908×M stage.
conclusionThe multivariate Cox regression model, which includes factors such as smoking status, tumor size, peritumoral GGO or nodules, surgery and M stage, is helpful in predicting the OS and risk stratification of s-NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.